Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High?

Group 1 - Arcus Biosciences, Inc. (RCUS) shares have increased by 1.2% over the past four weeks, closing at $21.96, with a mean price target of $34.6 indicating a potential upside of 57.6% [1] - The average of 10 short-term price targets ranges from a low of $20.00 to a high of $52.00, with a standard deviation of $10.17, suggesting variability in analyst estimates [2] - Analysts are optimistic about RCUS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RCUS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide guidance on the direction of price movement [14]